Treace Medical Concepts, INC 8-K filings

Treace Medical Concepts, Inc. reported second quarter 2026 revenue of $45.4 million, a 4% decrease year-over-year, alongside a net loss of $15.9 million, though the company raised its full-year Adjusted EBITDA guidance.

Treace Medical Concepts stockholders re-elected three directors, approved executive compensation, and ratified the appointment of Grant Thornton LLP.

Treace Medical Concepts reported a 10% decrease in first-quarter 2026 revenue to $47.2 million and an increased net loss of $18.0 million, while reaffirming full-year guidance.

Treace Medical Concepts announced preliminary Q1 2026 revenue between $47.0M-$47.2M and updated full-year 2026 guidance, alongside the departure of its Chief Commercial Officer.

Treace Medical Concepts reported full-year 2025 revenue growth of 2% to $212.7 million but saw a Q4 2025 revenue decrease of 9% and projects a 2026 revenue decline.

Treace Medical Concepts announced preliminary unaudited Q4 and full-year 2025 revenue, with full-year results meeting guidance despite a Q4 decline.

Treace Medical Concepts has secured a new $175 million debt financing package and appointed John K. Bakewell as lead independent director.

Treace Medical Concepts reported 11% revenue growth in Q3 2025 but revised its full-year guidance downward due to market headwinds and a shift in surgeon preferences.

Treace Medical Concepts reported improved second quarter 2025 financial results, including 7% revenue growth and reduced net loss, alongside the full market release of three new bunion technologies.

Treace Medical Concepts reports the outcomes of its 2025 Annual Meeting of Stockholders, including the election of directors, approval of executive compensation, and ratification of the independent accounting firm.

Treace Medical Concepts saw a slight revenue increase of 3% in Q1 2025, but significantly improved its adjusted EBITDA by 53% compared to the same period last year.

Treace Medical Concepts announces that John T. Treace will succeed James T. Treace as Chairman of the Board following the 2025 annual meeting of stockholders.

Treace Medical Concepts announces a 10% increase in Q4 revenue and a 12% increase in full-year revenue for 2024, driven by new technologies and surgeon adoption.

Treace Medical Concepts reported preliminary full-year 2024 revenue of $209.0 to $209.4 million, a 12% increase year-over-year, and added approximately 280 new active surgeons.

Treace Medical Concepts announced an 11% increase in revenue for the third quarter of 2024, alongside the launch of their new Nanoplasty 3D MIS System.

Treace Medical Concepts has initiated legal action against Stryker Corporation for alleged patent infringement and unfair competition related to its Lapiplasty bunion correction technology, while also reaffirming its financial outlook for 2024 and 2025.

Treace Medical Concepts announced a 6% increase in revenue for the second quarter of 2024, reaching $44.5 million, and reaffirmed its full-year revenue guidance.

Treace Medical Concepts held its 2024 annual meeting, where stockholders voted on the election of directors, executive compensation, and the ratification of the company's accounting firm.

Treace Medical Concepts announced a 21% increase in first-quarter revenue, driven by higher procedure kit volume and new technology adoption, while also revising its full-year revenue guidance due to increased market competition.

Treace Medical Concepts reported a 25% increase in fourth-quarter revenue and a 32% increase in full-year revenue for 2023, exceeding previous guidance, and anticipates significant progress towards profitability in 2024.